Clinical trial
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the…
NCT00055471 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00055471 |
|---|---|
| Title | A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms, Metastases, Neoplasm |
| Intervention type | Drug |
| Interventions | ZD4054 10 mg, ZD4054 15 mg, ZD4054 22.5 mg |
| Enrollment | 22 |
| Start date | Jun 1, 2003 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Mar 4, 2003 |
| Last update posted | Oct 31, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: